RNUGF OTC

ReNeuron Group plc is a UK-based biotechnology firm dedicated to the discovery, advancement, and eventual market launch of cutting-edge cell-based medical treatments. Their current pipeline features a CTX stem cell therapy, designed to improve outcomes for individuals suffering from stroke-related disabilities. Additionally, the company is progressing with its human retinal progenitor cell therapy, which is currently in Phase 2 clinical trials, aiming to address retinitis pigmentosa, a condition leading to blindness. Beyond these primary therapies, ReNeuron is also developing CTX-derived exosomes, which are microscopic packages of biological information released by CTX cells, and these are presently in the preclinical research stage. The company also offers licenses for its proprietary ReNcell product line. Demonstrating a commitment to collaborative research, ReNeuron has partnered with University College London to explore methods for generating immune cells from induced pluripotent stem cells, with the ultimate goal of developing novel anti-cancer cell therapies. Established in 1997, ReNeuron Group plc is headquartered in Pencoed, United Kingdom.